SequelSEC

IN8BIO, INC. INAB

Biological Products, (No Diagnostic Substances) · CIK 0001740279 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$19.44M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

IN8BIO, INC. (INAB) reported net income of -$19.44M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from IN8BIO, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

IN8BIO, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$19.44M-$30.44M-$30.01M-$28.52M-$14.65M-$8.56M
Net income-$19.44M-$30.44M-$30.01M-$28.52M-$14.65M-$8.56M
Research & development$10.21M$16.96M$16.83M$14.06M$7.35M$5.38M
Weighted-average diluted sharesshares 4.37Mshares 1.78Mshares 29.86Mshares 20.97Mshares 9.97MUnavailable
Pretax income-$19.44M-$30.68MUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0
Diluted EPS$-4.44$-17.05$-1.00$-1.36$-1.47Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$9.65M$12.64M$13.51M$14.46M$7.31M$3.18M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

IN8BIO, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$32.28M$20.94M$33.71M$33.04M$42.22M$20.91M
Current assets$27.88M$12.58M$24.62M$22.23M$38.98M$18.14M
Total liabilities$4.72M$6.47M$8.77M$10.31M$4.04M$2.59M
Current liabilities$3.16M$3.08M$5.39M$5.82M$2.26M$2.57M
Total equity incl. NCI$27.56M$14.48M$24.94M$22.73M-$38.18M-$16.58M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$34.90M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$309.00K$389.00K$924.00K$2.09M$395.00K$620.00K

Cash flow

IN8BIO, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$12.71M-$24.15M-$23.34M-$24.12M-$13.51M-$7.13M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0-$187.00K-$600.00K-$3.70M-$309.00K$0
Financing cash flow$28.64M$14.18M$27.04M$8.99M$32.96M$24.52M
Net change in cash$15.93M-$10.15M$3.10M-$18.84M$19.14M$17.38M
Stock-based compensation$3.19M$5.00M$4.37M$3.47M$2.20M$357.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

IN8BIO, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio8.82x4.08x4.57x3.82x17.28x7.05x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INAB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-12-31

Difference 76366000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.